BridgeBio Pharma, Inc.BBIONASDAQ

|||

Overview Charts News Fundamentals Key Metrics TTM Financials Earnings Growth Rating Analysts Institutional Peers Historical

Analyst Sentiment

Analysts lean bullish — 96% recommend buying.

Consensus Rating

Buy

25 analysts·High coverage

96%

Rating Distribution

Strong Buy

00%

Buy

2496%

Hold

14%

Sell

00%

Strong Sell

00%

Analyst ratings reflect Wall Street opinion, not guarantees. Historical accuracy varies by firm and sector.

Price Target Expectations

Analysts see moderate upside — consensus target 23% higher.

Bear Case

$69.00

-11%

Consensus

$95.00

+23%

Bull Case

$157.00

+103%

Price Range25 analysts

Low

Consensus

High

$69.00

$157.00

Current Target

Current Price

$77.27

Upside to Target

$17.73

Price targets are 12-month forecasts. Actual results depend on earnings, market conditions, and sector trends.

Earnings & Revenue Estimates

2026E$-1.58(10 analysts)

Actual

Estimate

Range (Low–High)

Stock Alarm Pro

Forward Growth Estimates (YoY)

FY2027

Rev+73.84%

EPS—

FY2028

Rev+53.60%

EPS+339.78%

FY2029

Rev+31.33%

EPS+58.98%

Earnings Surprises

Beat rate:33%(4/12 quarters)

Avg surprise:+2.4%

Beat

Miss

Inline

Estimate

Based on reported EPS vs consensus estimate.

Recent Analyst Actions

Jan 27, 2026Barclays

BridgeBio initiated with an Overweight at Barclays

Target:$157.00

+101.6%from $77.87

Jan 20, 2026Wells Fargo

BridgeBio price target raised to $88 from $84 at Wells Fargo

Target:$88.00

+15.4%from $76.26

Jan 8, 2026Truist Financial

BridgeBio price target raised to $86 from $80 at Truist

Target:$86.00

+15.8%from $74.27

Jan 6, 2026Morgan Stanley

BridgeBio initiated with an Overweight at Morgan Stanley

Target:$96.00

+30.8%from $73.42

Dec 15, 2025Leerink Partners

BridgeBio price target raised to $86 from $75 at Leerink

Target:$86.00

+15.3%from $74.59

Dec 11, 2025Bernstein

BridgeBio initiated with an Outperform at Bernstein

Target:$94.00

+29.3%from $72.70

Oct 30, 2025Truist Financial

BridgeBio price target raised to $80 from $66 at Truist

Target:$80.00

+25.2%from $63.88

Oct 30, 2025Oppenheimer

BridgeBio price target raised to $81 from $73 at Oppenheimer

Target:$81.00

+25.8%from $64.39

Oct 30, 2025Piper Sandler

BridgeBio price target raised to $98 from $93 at Piper Sandler

Target:$98.00

+47.1%from $66.62

Oct 30, 2025Goldman Sachs

BridgeBio Pharma (BBIO) PT Raised to $100 at Goldman Sachs

Target:$100.00

+50.1%from $66.62

Oct 29, 2025H.C. Wainwright

BridgeBio price target raised to $90 from $80 at H.C. Wainwright

Target:$90.00

+36.9%from $65.73

Oct 28, 2025H.C. Wainwright

BridgeBio price target raised to $80 from $70 at H.C. Wainwright

Target:$80.00

+26.3%from $63.33

Oct 27, 2025Raymond James

BridgeBio price target raised to $69 from $59 at Raymond James

Target:$69.00

+9.2%from $63.20

Oct 27, 2025Leerink Partners

BridgeBio Pharma (BBIO) PT Raised to $68 at Leerink Partners

Target:$68.00

+6.9%from $63.61

Aug 29, 2025H.C. Wainwright

BridgeBio price target raised to $70 from $56 at H.C. Wainwright

Target:$70.00

+35.9%from $51.51

Apr 30, 2025UBS

BridgeBio price target raised to $72 from $65 at UBS

Target:$72.00

+87.7%from $38.36

Oct 24, 2024Citigroup

Citi Reiterates Buy Rating on BridgeBio Pharma (BBIO)

Target:$45.00

+86.2%from $24.17

Oct 17, 2024Leerink Partners

BridgeBio price target lowered to $46 from $47 at Leerink

Target:$46.00

+74.6%from $26.34

Sep 11, 2024Piper Sandler

Piper Sandler Reiterates Overweight Rating on BridgeBio Pharma (BBIO)

Target:$46.00

+59.8%from $28.78

Sep 3, 2024Mizuho Securities

Mizuho Reiterates Outperform Rating on BridgeBio Pharma (BBIO)

Target:$53.00

+77.1%from $29.92

Jun 24, 2024Raymond James

Raymond James on BridgeBio Pharma (BBIO): 'We expect the topline nominal win for HELIOS-B will send BBIO shares downward'

Target:$46.00

+103.1%from $22.64

Jun 5, 2024BMO Capital

BMO Capital Reiterates Outperform Rating on BridgeBio Pharma (BBIO)

Target:$37.00

+37.4%from $26.93

Jun 5, 2024Wells Fargo

Wells Fargo Reiterates Overweight Rating on BridgeBio Pharma (BBIO)

Target:$58.00

+113.8%from $27.13

May 30, 2024Goldman Sachs

Goldman Sachs Reiterates Buy Rating on BridgeBio Pharma (BBIO)

Target:$50.00

+81.1%from $27.61

May 28, 2024UBS

BridgeBio Pharma (BBIO) PT Lowered to $47 at UBS

Target:$47.00

+68.2%from $27.94

Explore More

S&P 500 Screener

Filter and sort all 500 stocks

Market Movers

Today's biggest gainers and losers

Market Heatmap

Visual sector performance